CNSY (Cerenome) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNSY Cerenome Inc CNSY
29 GF Score
Price $2.02
! 1 Warning Sign
View Full Analysis

What is Cerenome Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cerenome  (NAS:CNSY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cerenome Cyclically Adjusted PS Ratio Related Terms


Cerenome Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Cerenome's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cerenome Cyclically Adjusted PS Ratio Chart

Cerenome Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cerenome Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNSY vs JSPR, MRKR, ALLR: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Cerenome's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerenome Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerenome's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cerenome's Cyclically Adjusted PS Ratio falls into.


CNSY
29GF Score
Cerenome Inc CNSY
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cerenome Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cerenome's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Cerenome's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.06/333.9520*333.9520
=0.060

Current CPI (Jun. 2026) = 333.9520.

Cerenome Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6,687.985 241.428 9,251.064
201612 13,288.417 241.432 18,380.718
201703 4,873.800 243.801 6,675.999
201706 5,813.838 244.955 7,926.120
201709 2,538.718 246.819 3,434.946
201712 3,003.993 246.524 4,069.338
201803 2,277.621 249.554 3,047.902
201806 2,733.520 251.989 3,622.636
201809 976.630 252.439 1,291.986
201812 901.439 251.233 1,198.240
201903 39,130.860 254.202 51,407.263
201906 255.925 256.143 333.668
201909 2,164.575 256.759 2,815.341
201912 114.802 256.974 149.192
202003 11.403 258.115 14.753
202006 17.116 257.797 22.172
202009 0.000 260.280 0.000
202012 0.000 260.474 0.000
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.998 296.808 1.123
202212 1.685 296.797 1.896
202303 5.453 301.836 6.033
202306 18.471 305.109 20.217
202309 9.611 307.789 10.428
202312 7.258 306.746 7.902
202403 9.701 312.332 10.373
202406 2.976 314.175 3.163
202409 4.634 315.301 4.908
202412 5.987 315.605 6.335
202503 1.817 319.799 1.897
202506 0.166 322.561 0.172
202509 0.325 324.800 0.334
202512 0.246 324.054 0.254
202603 0.155 330.213 0.157
202606 0.060 333.952 0.060

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cerenome Business Description

Other Exchanges XMP1:Germany
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
29GF Score

Get the complete analysis for CNSY

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02
Price